drugset / Trial / NCT04560816
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
Phase 1
Completed
57 enrolled
Alexion Pharmaceuticals, Inc.
ERT: Clinical Trial Technology Solutions · collabPPD Development, LP · collab
RandomizedCrossoverDouble-blindTreatment
Summary
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
Timeline
- Start
- 2020-07-24
- Primary completion
- 2021-03-24
- Completion
- 2021-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | TIOMOLIBDATE CHOLINE | Small molecule | 120 mg | Oral |
Indications
No indication recorded.